Related Experiment Videos
Insights
Short stature affects many children, with synthetic human growth hormone (somatropin) being a common treatment. This discussion explores somatropin
Area of Science:
- Pediatrics
- Endocrinology
- Genetics
Background:
- Short stature is a frequent pediatric concern, often linked to chronic illnesses or parental perception.
- Synthetic human growth hormone (somatropin) is a significant therapeutic option.
- Over 39,000 prescriptions for somatropin were issued in England in 2000, highlighting its prevalence.
Purpose of the Study:
- To review the role of synthetic human growth hormone in managing pediatric short stature.
- To discuss indications for growth hormone therapy beyond growth hormone deficiency.
Main Methods:
- Literature review and clinical practice discussion.
- Analysis of treatment indications and outcomes for somatropin therapy.
Main Results:
- Synthetic human growth hormone is used for various conditions causing short stature.
- Growth hormone deficiency, Turner's syndrome, and chronic renal insufficiency are key indications.
Conclusions:
- Synthetic human growth hormone plays a vital role in managing specific pediatric short stature cases.
- Appropriate patient selection is crucial for effective somatropin treatment.
Abstract:
Short stature is one of the commonest chronic problems encountered in paediatric practice, possibly because almost any long-term disease in children can slow growth and because parents may regard short stature as a disability in itself. For some, a potential treatment is growth hormone and, in England alone in 2000, over 39,000 prescriptions, costing more than 26.8 million Pounds, were dispensed for synthetic human growth hormone (somatropin), mostly for children. Here, we discuss the place of synthetic human growth hormone in the management of children with short stature associated with growth hormone deficiency or other conditions, such as Turner's syndrome and chronic renal insufficiency.